BC Week In Review | Jul 25, 2011
Company News

Vicept, Allergan deal

Allergan will acquire Vicept for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a topical cream targeting alpha adrenergic receptors on small...
BC Extra | Jul 20, 2011
Company News

Allergan buying Vicept

Allergan Inc. (NYSE:AGN) will acquire dermatology company Vicept Therapeutics Inc. (Malvern, Pa.) for $75 million up front and up to $200 million in development milestones, plus undisclosed sales milestones. Vicept's lead compound is V-101 , a...
BC Week In Review | Apr 25, 2011
Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-206 trial in 85 patients with moderate to severe erythema showed that V-101 met the primary endpoint of significantly reducing facial erythema from baseline over a 12 hour period...
BC Week In Review | Jan 17, 2011
Clinical News

V-101: Phase II data

The double-blind, U.S. Phase II Study V-101-ROSE-202 trial in 183 patients with moderate to severe erythema showed that once-daily 0.1% and 0.15% V-101 for 28 days met the primary endpoint of significantly reducing facial erythema...
BC Extra | Aug 13, 2010
Company News

Lundbeck discontinues U.S. development of Serdolect

H. Lundbeck A/S (CSE:LUN) discontinued development of Serdolect sertindole in the U.S. The company, which received an FDA complete response letter for the schizophrenia candidate last year, said it was not "beneficial to conduct more...
BC Week In Review | Aug 9, 2010
Clinical News

V-101: Phase I data

Preliminary data from a double-blind, crossover, U.S. Phase I trial in 22 patients with rosacea showed that V-101 had a side effect profile similar to that of placebo and significantly improved moderate to severe erythema...
BC Extra | Jun 30, 2010
Financial News

Vicept raises $10 million

Vicept Therapeutics Inc. (Malvern, Pa.) raised $10 million in a second close of a series A round, bringing the total raised in the round to $16 million. Vivo; Sofinnova Ventures; and Fidelity Biosciences led the...
BioCentury | Jul 27, 2009
Product Development

Parsing the Dimebon spike

Elevated beta amyloid is generally believed to be one of the causal mechanisms in the pathology of Alzheimer's disease. Thus it was surprising when data presented at this month's International Conference on Alzheimer's Disease in...
BC Week In Review | Jun 29, 2009
Clinical News

Serdolect sertindole regulatory update

H. Lundbeck said it received a complete response letter from FDA for an NDA for Serdolect sertindole to treat schizophrenia. The company said FDA requested additional data to "better understand the appropriate patient population" for...
BC Extra | Jun 26, 2009
Company News

FDA wants more Serdolect data

H. Lundbeck A/S (CSE:LUN) said it received a complete response letter from FDA for an NDA for Serdolect sertindole to treat schizophrenia. The company said FDA requested additional data to "best understand the appropriate patient...
Items per page:
1 - 10 of 46